Ken Griffin Royalty Pharma PLC Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$25.63 - $29.27 $1.02 Million - $1.16 Million	-39,800 Reduced 31.61%	86,100 $2.44 Million
Q2 2024 Aug 14, 2024	BUY	$26.26 - $29.9 $1.17 Million - $1.33 Million	44,600 Added 54.86%	125,900 $3.32 Million
Q1 2024 May 15, 2024	BUY	$27.46 - $31.33 $804,578 - $917,969	29,300 Added 56.35%	81,300 $2.47 Million
Q4 2023 Feb 14, 2024	SELL	$26.21 - $29.22 $466,538 - $520,116	-17,800 Reduced 25.5%	52,000 $1.46 Million
Q3 2023 Nov 14, 2023	BUY	$26.26 - $31.38 $186,446 - $222,798	7,100 Added 11.32%	69,800 $1.89 Million
Q2 2023 Aug 14, 2023	SELL	$29.6 - $36.56 $580,160 - $716,576	-19,600 Reduced 23.82%	62,700 $1.93 Million
Q1 2023 May 15, 2023	BUY	$32.77 - $39.4 $724,217 - $870,740	22,100 Added 36.71%	82,300 $2.97 Million
Q4 2022 Feb 14, 2023	SELL	$39.17 - $44.04 $5.33 Million - $5.99 Million	-136,000 Reduced 69.32%	60,200 $2.38 Million
Q3 2022 Nov 14, 2022	SELL	$39.88 - $44.65 $2.19 Million - $2.45 Million	-54,900 Reduced 21.86%	196,200 $7.88 Million

412

283M

578K

47.5K

Ticker RPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 437,139,008
Market Cap $11.2B
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.